Clinical Trial Search

Primary: Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity — 17.2; 21.9; 29.7; 45.3 Percentage of Participants

Primary: Percentage of Participants With 1 or More Unsolicited AE : Vaccination 1 — 60.0; 70.0; 50.0; 44.4 Percentage of participants

Primary: Mortality — 13; 8 Participants

Primary: Titers of ZEBOV-specific IgG Antibodies — 1227; 25; 344.5 ELISA units per ml

Primary: Mortality — 93; 61; 52; 84 deaths

Primary: Number of Participants With One or More Solicited Local Treatment-Emergent Adverse Events (TEAE) — 8; 8; 10; 3 Participants

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 7 Days After the cAd3-EBO S Vaccine Administration — 3; 3; 6; 16 Participants

Primary: Serious Adverse Events. — 6; 6; 8 Participants — p=0.68

Primary: Number of Participants With Solicited Adverse Events Following V920 Vaccination — 5; 1; 2; 1 Participants

Primary: Laboratory-confirmed Ebola (Study Diagnostics) — 0; 0 Participants

Primary: Proportion of EVD Survivors With Evidence of Persistence of Ebola Viral RNA in Ocular Tissue — 0 Participants

Primary: Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms…

Primary: Number of Subjects Experiencing Infusion Reaction During Product Administration — 0; 0; 0; 3 Participants

Primary: Percentage of Participants With Ebola Virus Glycoprotein (GP-EBOV) Antibody Response — 40.9; 75.7; 81.1; 2.7 percentage of participants — p=<.001

Primary: Safety and Tolerability of Administration of ChAd3-EBO Z and MVA-EBO Z 7 Days Later. This Will be Done by Recording the Number of Participants Who Experience Adverse…

Primary: Survival at Day 14 After Start of Intervention — 58; 260 Participants

Primary: Number of Subjects With Solicited Local Adverse Events — 356; 57; 3; 0 Participants

Primary: Mean Assay Negativity Rate (ANR) for Ebola Virus During the Treatment Phase — 0.85; 0.76 proportion of semen samples

Primary: Number of Participants With Adverse Events (Day 29) — 96; 17; 68; 17 Participants

Primary: Geometric Mean Concentrations (GMCs) of Binding Antibody Levels Against the Ebola Virus Glycoprotein (EBOV GP) as Measured by Enzyme-linked Immunosorbent Assay (ELISA)…

Primary: Stages 1 and 2: Number of Participants With Solicited Local Adverse Events (AEs) (Day 8) — 12; 51; 17; 14 Participants

Primary: Number of Participants With Unsolicited Adverse Events (Groups 1, 2 and 3) — 4; 6; 6; 62 Participants

Primary: Number of Participants With Clinical Safety Laboratory Adverse Events — 2; 5; 4; 2 Participants

Primary: Part 1, Part 2 (Group 2): Number of Participants With Unsolicited Adverse Events — 33; 10; 32; 3 Participants

Primary: Geometric Mean Titer of Anti-ZEBOV Glycoprotein Antibody — 1183.9; 1266.0; 1346.0; 1291.9 EU/mL — p=<0.001

Primary: Number of Subjects With Solicited Local Symptoms, Overall — 127; 60; 4; 0 Participants

Primary: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms For 7 Days After Each Product Administration — 4; 2; 0; 1 Participants

Primary: Number of Participants With Solicited Local (at the Administration Site) Adverse Events — 18 Participants

Primary: Assessment of DENV, ZIKV, CHIKV Seroprevalence Via Screening PRNT50 Titers in Cambodian Adults. — 300 Participants